Skip to content

â??To Evaluate The Efficacy Of Pratisaraneeya Muskak Kshara In The Management Of Arsha(INTERNAL HAEMORRHOIDS)â??

â??Clinical Evaluation Of Pratisaraneeya Muskak Kshara In The Mwnagement Of Arsha. (INTERNAL HAEMORRHOIDS)â??

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/07/026518
Enrollment
50
Registered
2020-07-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K641- Second degree hemorrhoids

Interventions

Intervention1: Pratisaraneeya muskak kshara in haemorrhoids: Tikshna Pratisaraneeya muskak kshara(5gm Per Haemorrhoid) will be applied in internal haemorrhoids(Ano Rectal Route) for 1 to 2 minutes an

Sponsors

Government akhandanand ayurved college
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: patients suffering from first and second degree internal haemorrhoids and they will enrolled irrespective of gender cast religion and having controlled Diabetes mellitus and Hypertention

Exclusion criteria

Exclusion criteria: Age having less than 18 years and more than 60 years having third and fourth degree haemorrhoids and other disease like rectal prolepse thrombosed piles malignancy of anorectum HIV positive HBsAG positive kochs disease and other systemic disorders and having uncontrolled Hypertention and Diabetes mellitus cardiac disorders and also pregnant women

Design outcomes

Primary

MeasureTime frame
Result will be assessed on the basis of symptoms of bleeding pain and dischargeTimepoint: 3 weeks

Secondary

MeasureTime frame
Comparing protrusion of pile mass per rectum by degree of prolepseTimepoint: 3 weeks

Countries

India

Contacts

Public ContactDr Harshit s shah

GOVERNMENT AKHANDANAND AYURVED COLLEGE AND HOSPITAL

sejharsh@gmail.com9824068760

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026